- Second quarter revenue increased 41% from prior year, to $80.2 million - Adjusted EBITDA increased 25% to $16.8 million - Quarterly paid downloads increased 30% to a record 31.5 million
- Collection grew 42%; currently exceeds 40 million images, 1.9 million video clips - Music licensing launched during the quarter - Total customer count exceeds 1 million NEW YORK , Aug.
Silgan Holdings Inc. (Nasdaq:SLGN), a leading supplier of rigid
packaging for shelf-stable food and other consumer goods products,
announced today that its Board of Directors has declared a quarterly
cash dividend on its common stock.
Net Income (Loss) - $(0.3) million Adjusted; $12.1 million GAAP
Revenue - $122.8 million Adjusted (Education down 19%, Enterprise up 45% year-over-year); $137.5 million GAAP
Adjusted EBITDA - $10.3 million
Unveiled new SMART kapp™ capture board
Launched SMART amp™ and Notebook Advantage education software
Launched SMART Board 6065 education interactive flat panel
CALGARY, Alberta, Aug.
U.S. Forest Service, the National Association of State Foresters, and the Ad Council honor iconic PSA figure with Washington, D.C. birthday celebration, Instagram campaign and a re-launched zip code
WASHINGTON , Aug.
- Net revenue of $460 million, a 4.8% increase over prior year - Earnings per diluted share of $0.29 excluding special items, a 21% increase over prior year
- Earnings per diluted share of $0.16 including special items - Closed on the Baptista's acquisition and finalized efforts to sell Private Brands - Initiated Margin Improvement & Restructuring Plan CHARLOTTE, N.C. , Aug.
Solazyme, Inc. (NASDAQ:SZYM), a renewable oil and bioproducts company,
today announced its participation in the Jefferies 2014 Global
Industrials Conference and the Pacific Crest 16 th Annual
Global Technology Leadership Forum.
Networks , Inc. (Nasdaq: SONS), a global
leader in securing real-time communications , today announced that
the Sonus SBC SWe (Software edition) has achieved Microsoft Lync 2013
qualification for Session Border Controller (SBC) deployments.
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a
biopharmaceutical company developing PRX302 for the treatment of the
symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and
for the treatment of localized prostate cancer, today announced
financial results and recent key operational and financial highlights
for the three and six months ended June 30, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.